Xizhou Zhang1,#, Zetao Zhang1,#, Jianguang Lin2, Jiarong Yi3, Xuxiazi Zou3, Jikun Feng3, Guangsheng Huang1, Bingfeng Chen1, Junxi Long1, Fengjia Wu3, Feng Ye3,*, Haoming Wu1,*
Oncology Research, Vol.33, No.9, pp. 2529-2547, 2025, DOI:10.32604/or.2025.065029
- 28 August 2025
Abstract Background: Breast cancer remains a leading cause of morbidity and mortality among women worldwide, with significant geographic disparities in its impact. While human epidermal growth factor receptor 2 (HER2)-targeted therapies, such as trastuzumab, have improved outcomes for HER2-positive breast cancer, challenges like therapy resistance persist, highlighting the need for novel treatments. Recent developments in antibody-drug conjugates (ADCs), particularly disitamab vedotin (RC48), show promising efficacy in targeting both HER2-positive and HER2-low expression tumors, warranting further investigation through real-world studies to assess its broader clinical applicability. Method: This retrospective, multicenter observational study evaluated the real-world efficacy and… More >
Login
Register
